Dia.Metra S.r.l.’s Post

👉 Anti-Müllerian hormone as a diagnostic biomarker for Polycystic Ovary Syndrome (PCOS) and Polycystic Ovarian Morphology (PCOM): a systematic review and meta-analysis 📚 https://lnkd.in/d8aWq9yW

p53 is one of the most complex & interesting proteins in the proteome...

Primary biliary cholangitis (PBC) is the most common liver disorder in systemic sclerosis (SSc), with an estimated prevalence of 3%–50%. This association is known as Reynolds’ syndrome and it was first described in 1971. A recent GWAS meta-analysis shows evidence of shared causal variants between PBC and SSc for nine loci, five of which are novel: CD40, ERAP1, PLD4, SPPL3, and CCDC113. The CD40 risk locus colocalizes with trans-protein quantitative trait loci of multiple plasma proteins involved in B cell function. 🔗https://lnkd.in/dpuFfbjQ

Gene&Cell Therapy >> Autoimmune CAR-Ts are under the microscope after Cabaletta’s safety issue in lupus: Eyes are on CAR-T therapy clinical trials in autoimmune diseases for potentially more serious side effects, after Cabaletta’s Bio’s candidate was linked with a high-grade neurotoxicity event in one lupus patient. Cabaletta said Thursday that a patient with lupus nephritis given CABA-201 experienced grade 4 immune effector cell-associated neurotoxicity syndrome, or ICANS. The event was resolved after “standard management,” and Cabaletta is amending its trial protocol to increase monitoring for fevers and neurologic symptoms and to include seizure prophylaxis, the company said. Although high-grade ICANS is a known risk of CAR-T therapies, it hasn’t occurred in clinical trials of autoimmune patients until now, TD Cowen analysts said. Investors could therefore be concerned that Cabaletta’s contender carries a greater risk of the side effect, they added. But concerns could extend beyond Cabaletta’s drug, Leerink analysts said, adding that they “do not rule out” more serious cases of ICANS or cytokine release syndrome occurring in autoimmune patients treated with CAR-T therapies in the future. Other companies with CAR-T therapy focused on autoimmune disease include Kyverna Therapeutics and China’s Gracell Biotechnologies. Kyverna is developing KYV-101 for lupus nephritis and systemic sclerosis, while Gracell — which AstraZeneca bought in December for $1 billion — is advancing GC012F for systemic lupus erythematosus. “These are early days for CAR T in [autoimmune disease], and we suspect part of the trailblazing process will be learning to identify and select the right patients,” Stifel analysts said. Autoimmune studies of CAR-T therapies usually enroll patients with severe, life-threatening disease who have failed multiple lines of treatment. This is because the drug class comes with a risk of severe side effects, which wouldn’t be worth taking for autoimmune patients with more mild or moderate disease. Cabaletta is running the open-label Phase 1/2 RESET-SLE trial of the CAR-T in systemic lupus erythematosus and lupus nephritis. The patient with grade 4 ICANS had refractory disease, was taking five to six medications for lupus and had experienced febrile events that led to hospitalization before CABA-201 administration, the Stifel analysts wrote. The company’s share price $CABA plummeted 41% to close at $4.01 on Thursday. The stock drop could have been driven by concerns about monitoring and managing autoimmune patients taking autologous CAR-T therapies and implications for the “scope of commercial use,” the Stifel analysts said. But use could broaden beyond “very severe patients” as drugmakers and physicians get more experience with managing side effects, the analysts added. #lucidquest #genetherapy #celltherapy

The science class is open. Welcome today's protagonist - aloe-emodin Aloe-emodin is an anthraquinone compound, mainly derived from the dried roots and rhizomes of rhubarb (Rheum palmatum L.), Tanguticum Maxim.ex Balf. or medicinal rhubarb (Rheum officinale.Baill.). Aloe-emodin is the antibacterial active ingredient of rhubarb, which is sensitive to staphylococci and streptococci. Aloe-emodin also has the effect of inhibiting the biosynthesis of DNA, RNA and protein in cancer cells. Get a quote: https://lnkd.in/gFWbU3kP #aloe #plantextract #powder #ingredient #rhizomes #skincare #cosmetics #healthcare

Check out my recent talk with Heather Sandison, ND on "Reversing Alzheimer's" To catch the full show, visit: https://lnkd.in/gBJs8E_W #Alzheimers #Bredesen #cognition #mold #microbiome #virus #amyloid #ketosis #limbic #vagal #sleep #epigenetics #seedoils #coagulation #EMFs, #mitochondria, #peptides

What makes an estrogen “good or bad”? This has to do with the biological activity, or potency, of that estrogen. Estrogens are important in a host of cellular activities that affect growth and differentiation in various target cells. This is normal and beneficial, but too much estrogenic stimulation can have a negative effect. In premenopausal women, the ovaries produce the estrogen estradiol (E2), which converts into estrone (E1), both of which must eventually be broken down and excreted from the body. This breakdown occurs primarily in the liver, and the excreted metabolites flow out in the bile or urine. Estradiol and estrone undergo this breakdown through a process called hydroxylation. Therefore, properly metabolizing and excreting estrogens is crucial. If these estrogens are metabolized into the 2-hydroxylated estrone and estradiol, they lose much of their cell proliferative and estrogenic activity and are termed “good” estrogen metabolites. Studies show that when 2-hydroxylation increases, the body resists cancer, and that when 2-hydroxylation decreases, cancer risk increases. This is why testing the metabolites of estrogen in your urine is superior to simply testing blood markers of estrogen alone. Both a DUTCH or Meridian valley urine test offer this. You can order your test at the link in my bio.👆 #pcossupport #fertilityhealthtips #hormonesupport #periodcramps #adrenalsupport #pcosawareness #periodproblems #fertilitytips #adrenalhealth #painfulperiods #ovulationmatters #periodproblems #heavyperiods

51-year-old Hispanic male with mCRPC and HRRm Presented 2020, PSA 55 Gleason 5+4=9; Mets: mediastinum, L sacrum, ribs Germline: BRCA2 mutation Treated with upfront docetaxel ADT, enzalutamide, denosumab PSA rising with PSADT 6 months Treated with a PARP-i 3. He calls to report right lower leg is warm, painful and swollen. What is the best course of action? a.Reassure him this is a normal side effect and will resolve. b.Encourage elevation of right lower leg. c.Order venous duplex ultrasound.

Check out my recent talk with Heather Sandison, ND on "Reversing Alzheimer's" To catch the full show, visit: https://lnkd.in/gBJs8E_W #Alzheimers #Bredesen #cognition #mold #microbiome #virus #amyloid #ketosis #limbic #vagal #sleep #epigenetics #seedoils #coagulation #EMFs, #mitochondria, #peptides

Interesting read: Precision medicine and nucleotide-based therapeutics to treat MASH. Oligonucleotide-based therapies, namely small-interfering RNA (siRNA) and antisense oligonucleotide (ASO), have been recently developed to tackle MASLD (Metabolic dysfunction-associated steatotic liver disease) by reducing the expression of genes influencing MASH progression, such as PNPLA3 and HSD17B13. Here, we review the latest progress made in the synthesis and development of oligonucleotide-based agents targeting genetic determinants of MASH. cmh-2024-0438.pdf (e-cmh.org)